https://orcid.org/0000-0002-8000-8883
References
- Gaiser MR, Lorenzen S, Merx K, et al. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: a thorough gender-specific analysis using the WoMo score. Cancer Med 2019;8:4169–4175.
- Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16–26.
- Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3–S8.
- Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer 2016;24:3943–3950.
- Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol 2014;71:217e211.
- Clabbers JMK, Boers-Doets CB, Gelderblom H, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 2016;24:513–521.
- Peng Y, Li Q, Zhang J, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends 2019;12:537–552.
- Beech J, Germetaki T, Judge M, Paton N, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol 2018;14:2531–2541.
- Kafatos G, Dube S, Burdon P, et al. Management of EGFR inhibitor-induced skin toxicity and factors impacting patients' adherence to skin toxicity treatment: health care provider and patient surveys in European Oncology Centers. Clin Colorectal Cancer 2020;19(2):100–108.e9.
- Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 2017;25:651–660.
- Billi AC, Sarkar MK, Gudjonsson JE. When bugs and drugs conspire: driving acneiform skin toxicity. J Clin Invest 2020;130:1090–1092.
- Pinto C, Barone CA, Girolomoni G, et al. Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian Expert Recommendations. Am J Clin Oncol 2016;39:407–415.
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803–812.
- Nanney LB, Stoscheck CM, King LE, Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742–748.
- Chularojanamontri L, Tuchinda P, Likitwattananurak C, et al. Cutaneous toxicities of epidermal growth factor receptor inhibitors: a prospective study in 60 Asian patients. Asian Pac J Allergy Immunol 2019;37:12–18.
- Hirayama K, Su Y, Chiba M, et al. Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: a literature review. Jpn J Nurs Sci 2020;17(3):e12321.
- Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152–159.
- Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657–670.
- Valentine J, Belum VR, Duran J, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 2015;72:656–667.
- Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012;67:400–408.